Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results
Michael C. Heinrich(VA Portland Health Care System), Laurence H. Baker(Memorial Sloan Kettering Cancer Center), Christopher L. Corless(Oregon Health & Science University), William D. Tap(Memorial Sloan Kettering Cancer Center), Kouros Owzar(Duke University), Charles D. Blanke(SWOG Cancer Research Network), Christopher W. Ryan(Oregon Health & Science University), Robert S. Benjamin(The University of Texas MD Anderson Cancer Center), Dennis A. Priebat(Washington Hospital), George D. Demetri(Dana-Farber Cancer Institute), Robert G. Maki(Memorial Sloan Kettering Cancer Center), Margaret von Mehren(Temple University Health System), John J. Crowley(Spanish Head & Neck Cancer Cooperative Group), Jonathan A. Fletcher(Harvard University), Cathryn Rankin(Cleveland Clinic), Ernest C. Borden(Cleveland Clinic), Martin E. Blackstein(Mount Sinai Hospital)
Cited by 126
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k